Brad Wouters

Overview

Unlike most tissue, tumour cells can survive and thrive in environments starved of oxygen. Characterized by extreme differences in nutrient supply, pH, and oxygenation, these environments promote tumor malignancy and prevent effective treatment for patients.

Dr. Wouters’ lab has identified new signaling pathways that influence how tumours respond to environments with reduced oxygenation. Using high-throughput approaches the lab is defining the molecular basis of these signaling pathways and establishing their importance for future cancer therapies.

Contact Information

Dr. Brad Wouters

Telephone: 416-581-7840

Affiliations

2008 - Senior Scientist and Director, Hypoxia and Microenvironment Program, Ontario Cancer Institute.
2008 - OICR Senior Investigator, Ontario Institute for Cancer Research (OICR).
2008 - Professor, Department of Radiation Oncology, University of Toronto.
1998 - Postdoctoral fellow, School of Medicine, Department of Radiation Oncology, Stanford University.
1996 - PhD in Physics, Department of Medical Biophysics, Supervisor: Dr. Lloyd D. Skarsgard., University of British Columbia.
2005 - 2008Full Professor and Head Scientist, Maastricht Radiation Oncology Laboratory (Maastro Lab) azM/University of Maastricht/GROW Research Institute, GROW Research Institute.
2001 - 2005Associate Professor and Head Scientist, Maastricht Radiation Oncology Laboratory (Maastro Lab ) azM/University of Maastricht, GROW Research Institute.
1999 - 2001Assistant Professor, Department of Radiology, Faculty of Medicine, University of Ottawa.
1999 - 2001Associate Research Scientist, Research Institute, Ottawa General Hospital.
1998 - 2001Career Scientist, Centre for Cancer Therapeutics, The Ottawa Hospital Cancer Centre (TOHCC).

Research Output

  • Magagnin MG, VandenBeucken T, Sergeant K, Lambin P, Koritzinsky M, Devreese B and Wouters BG
    The mTOR target 4E-BP1 contributes to differential protein expression during normoxia and hypoxia through changes in mRNA translation efficiency
    • 2008;Proteomics:8.
  • Koritzinsky M, Rouschop KM, van den Beucken T, Magagnin MG, Savelkouls K, Lambin P, Wouters BG
    Phosphorylation of eIF2alpha is required for mRNA translation inhibition and survival during moderate hypoxia
    • Radiother Oncol. 2007;83(3):353-61
  • Chiu RK, Brun J, Ramaekers C, Theys J, Weng L, Lambin P, Gray DA, and Wouters BG
    Lysine 63-polyubiquitination guards against translesion synthesis-induced mutations
    • PLOS Genetics. 2006;2:e116
  • Koritzinsky M, Magagnin MG, van den Beucken T, Seigneuric R, Savelkouls K, Dostie J, Pyronnet S, Kaufman RJ, Weppler SA, Voncken JW, Lambin P, Koumenis C, Sonenberg N, and Wouters BG
    Gene expression during acute and prolonged hypoxia is regulated by distinct mechanisms of translational control
    • EMBO Journal. 2006;25:1114-1125
  • Koumenis C, Naczki C, Koritzinsky M, Rastani S, Diehl A, Sonenberg N, Koromilas A, Ron D, Wouters BG
    Regulation of protein synthesis by hypoxia via activation of the endoplasmic reticulum kinase PERK and phosphorylation of the translation initiation factor eIF2alpha
    • Mol Cell Biol. 2002;(21):7405-16